Posted by Michael Wonder on 06 Dec 2024
Positive CHMP opinion for the extension of indication of Palforzia for the treatment of toddlers with confirmed peanut allergy
2 December 2024 - Stallergenes Greer today announced that the CHMP of the EMA provided a positive opinion for the extension of the existing indication for Palforzia (defatted powder of Arachis hypogaea L., semen (peanuts)) to the treatment of toddlers (ages 1 to 3) with a confirmed diagnosis of peanut allergy.
If the extension indication is granted by the European Commission, Palforzia will become the first EMA approved oral immunotherapy treatment for toddlers living with confirmed peanut allergy.
